Innopain is a biopharmaceutical company, based in Clermont Ferrand (France), focused on discovering and developing new chemical entities, first-in-class analgesic drugs, to treat pain, without inducing many of the side effects associated with current therapies.
Our ambition is to develop innovative compounds to reach the human proof of concept (clinical trials phase 2) of efficacy and safety for moderate to severe acute and chronic pain.
The development of these compounds, TREK-1 agonists, is the result of our world-class research in pharmacology and medicinal chemistry especially on the involvement of TREK-1 and its direct activation, acting downstream from the µ-opioid receptor (µOR), having strong analgesic effects without opioid-like adverse effects.
President & CEO, formerly founder and President of a CRO Creapharm. Michel had earlier spent many years in international executive positions with Big Pharma companies. He earned an MBA at Harvard following economics post graduate studies in France.
Project manager, Antoine was chemical engineer at Innopain before he was promoted to project manager. He graduated from ENSCR (Ecole National Supérieure de Chimie de Rennes) after participating in the preclinical development of an API.
This team is backed by a Scientific Advisory Board of top performing experts with complementary expertise in :
Innopain maintains close scientific collaboration with the specialized Analgesia labs where the project originated in order to keep up to date on the advancements in the domain of pain.
Today, morphine remains the treatment of reference for severe acute or chronic pains. Its analgesic effect is often accompanied by adverse side effects such as constipation, respiratory depression, and dependence.
This opioid drug produces its pharmacological action by interacting with the μ-opioid receptor (μOR).
Pharmacologists from Professor Eschalier team (Neurodol – UMR 1107 Inserm Université d’Auvergne) and Professor Lazundski & Lesage team (IPMC UMR7275) reported that the beneﬁcial and adverse effects of morphine could be dissociated by demonstrating that TREK-1 contributed to the analgesic effect of morphine but not to its adverse side effects.
These observations suggest that direct activation of the TREK-1 channel by acting downstream from μOR might have a strong analgesic effect without opioid-ligand adverse effects
In vivo they have demonstrated that analgesia is the direct result of activating the TREK-1 potassium channel.
This significant discovery was published in Nature in 2013 after securing a patent covering the screening for pain of TREK and TRAK agonists(1).
In addition, the team’s chemists have (Professor Sylvie Ducki) synthesized a family of agonists NCEs which are protected by a second patent.
Further development has enabled the identification of a lead compound coded RNE 28 which shows promising in vivo activity and safety(2)(3).
Innopain has an exclusive worldwide license of these two patents and our mission is to develop this innovative approch to treat pain, acute and chronic.
Innopain develops original analgesics to replace morphine without its side effects.
The objective of Innopain is to reach the Proof Of Concept for intravenous and oral administration, for acute and chronic pain. Our strategy is to quickly reach these POC with an optimized development plan.
Since the beginning of Innopain (August 2015) we have focused on 3 main steps: drug substance development, validation of the efficiency in animals, safety of compound in animal models and absence of side effects like constipation, dependency and addiction.
RNE28 is a new chemical entity, for intravenous and oral administration, susceptible to be the first representative of a new class of analgesic drugs. Innopain aims to develop this major pharmacological innovation from preclinical to clinical Phase II and to demonstrate safety and efficacy in human.
(1) Activation of TREK-1 by morphine results in analgesia without adverse side effects - Nature Communications|4:2941|DOI: 10.1038, 2013 - Maıly Devilliers, Jérôme Busserolles, Stéphane Lolignier, Emmanuel Deval, Vanessa Pereira, Abdelkrim Alloui, Marine Christin, Bruno Mazet, Patrick Delmas, Jacques Noel, Michel Lazdunski & Alain Eschalier
(2) Synthesis and structure- activity relationhip study of substituted caffeate esters as antinociceptive agents modulating the TREK-1 chanel. - Europenan Journal of Medicinal Chemistry 75 391-402,2014 - Nuno Rodriguez, Khalili Bennis, Delphine Vivier, Vanessa Pereira, Franck C Chatelain, Eric Chapuy, Hemantkumar Deokar, Jérôme Busserolles, Florian Lesage, Alain Eschalier, Sylvie Ducki.
(3) Development of the First Two-Pore Domain Potassium Channel TWIK-Related K+ Channel 1 Selective Agonist Possessing in Vivo Antinociceptive Activity - Journal of Medicinal Chemistry 60, 1076-1088, 2017 - Delphine Vivier,Ismail Ben Soussia, Nuno Rodrigues, Stéphane Lolignier, Maïly Devilliers, Franck C. Chatelain, Laetitia Prival, Eric Chapuy, Geoﬀrey Bourdier, Khalil Bennis, Florian Lesage, Alain Eschalier, Jérôme Busserolles and Sylvie Ducki
An innovative positioning
New pharmacological target :TREK-1
Non opiod first-in-class NCE
Every day more than 90 Americans die from opioid misuse and addiction
Major Public Health Issue
Acute and chronic pain is responsible of 90% of medical consultations
Chronic pain affects over 1,5 billion people worldwide
To develop new analgesic drugs for patient benefit
Innovative pharmacological approach
To treat acute and chronic pain
Optim’Dol is a program which benefits of a partial financing from European FEDER (Fonds Européen de Développement Régional)
This program fits within one of the strategic innovation domains supported by the region Auvergne Rhone Alpes, i.e. the prevention and treatment of pain. This region regroups within the Analgesia cluster several university research teams in pharmacology and chemistry, and private companies which have been collaborating for several years in the field of pain, notably to develop new innovative drug candidates. These collaborations have led to the creation of the Analgesia Institute, which has been certified by the French Research Ministry (MESR) as a research foundation. Indeed, this recognizes the expertise gathered over 20 years in the analysis and approaches of pain pathologies, and of the public-private collaborations initiated over the last 8 years. Optim’dol regroups 2 companies, ANS Biotech and Innopain, and 2 research teams Neurodol-Auvergne University for pharmacology and ICCF-Sigma University for chemistry all part of Analgesia Institute. The objective of the program, through this multidisciplinary collaboration, is to design and develop new analgesic non opioid chemical entities to treat acute and chronic moderate to severe pain.
This program takes advantage of complementary expertise: research of each member will enrich the joint program, cross feeding to speed the development of new qualified NCEs and pharmacological services. Innopain shall interface with ANS to screen the molecules issued from the works of ICCF and Neurodol. ANS shall be in in a position to further qualify the tests initiated by Neurodol applied to the Innopain’s molecules and to offer optimized preclinical services to potential clients.
This synergy of expertise, applied to market needs, will contribute to progress and speed up preclinical research.
The financial subsidy obtained for this program comes from FEDER and is linked to Initiative for Innovation in Healthcare S3 (2016-2018): optimization of drug candidates for pain treatment.
2018 BIO International Convention BIO is Back in Boston to Celebrate 25 Years of Innovation The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represe...
2018 BIO International Convention
BIO is Back in Boston to Celebrate 25 Years of Innovation
The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.
In 2017, 107 young innovative companies applied to the French national competition to participate in the NETVA program. These candidates went through two selection processes, the first taking place in...
In 2017, 107 young innovative companies applied to the French national competition to participate in the NETVA program. These candidates went through two selection processes, the first taking place in Paris, and the second in one of the four NETVA cities: Boston, San Francisco, Toronto and Washington, DC. The Ministry for Europe and Foreign Affairs and its partners are proud to present the 20 French startups which have been selected to take part in the 2017 edition of NETVA which offers a personalized support program in order to familiarize them with the North American markets.
2017 NETVA Laureates going to Boston
There’s no better place to connect with biotech’s top people and most innovative technologies than at BIO 2017. The ideas shared here go beyond professional development. Experience powerful business p...
There’s no better place to connect with biotech’s top people and most innovative technologies than at BIO 2017. The ideas shared here go beyond professional development. Experience powerful business partnering, benefit from invaluable education sessions and network with 16,000+ of the industry’s brightest.
BioEquity Europe 2017, the 18th collaborative gathering of the corporate investment communities for the European life sciences, took place 22 – 23 May in Paris, France. Bio€quity Europe is the seminal...
BioEquity Europe 2017, the 18th collaborative gathering of the corporate investment communities for the European life sciences, took place 22 – 23 May in Paris, France. Bio€quity Europe is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects. Bio€quity Europe has showcased more than 700 leading European companies to thousands of investment and pharma business development professionals.
Now running for almost two decades, SMi Group are delighted to announce the return of its 17th annual Pain Therapeutics conference, taking place on the 22nd – 23rd May 2017 in London, and featur...
Now running for almost two decades, SMi Group are delighted to announce the return of its 17th annual Pain Therapeutics conference, taking place on the 22nd – 23rd May 2017 in London, and featuring a half day post-conference workshop on the 24th May!
Aimed at an audience of scientific leaders and senior specialists in neuroscience, CNS, clinical operations and pharmacology, the 17th annual show will provide a focal point for the industry to assess new innovations in effective and safe pain management.
Afin de favoriser la création d’entreprises de technologies innovantes, le ministère chargé de la Recherche organise chaque année un Concours national d’aide à la création d’entreprises de technologie...
Afin de favoriser la création d’entreprises de technologies innovantes, le ministère chargé de la Recherche organise chaque année un Concours national d’aide à la création d’entreprises de technologies innovantes, volet de i-LAB. Ce concours, organisé en partenariat avec BpiFrance, permet de soutenir les meilleurs projets de création d’entreprises de technologies innovantes, en leur offrant une aide financière et un accompagnement adapté.
Dans la dynamique de simplification engagée par le secrétaire d’Etat, le concours a évolué à l’occasion de sa 18e édition et se recentre désormais sur la catégorie « création-développement ».
Le jury national a distingué 56 lauréats « création-développement » dont Innopain parmi les 347 candidatures reçues au concours national.